NASDAQ:CMMB Chemomab Therapeutics (CMMB) Stock Price, News & Analysis $1.27 +0.08 (+6.72%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.3450-Day Range$0.82▼$1.4252-Week Range$0.42▼$1.58Volume196,836 shsAverage Volume176,590 shsMarket Capitalization$14.03 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Chemomab Therapeutics alerts: Email Address Chemomab Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside346.2% Upside$5.67 Price TargetShort InterestHealthy0.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.80) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector461st out of 936 stocksPharmaceutical Preparations Industry212th out of 436 stocks 3.6 Analyst's Opinion Consensus RatingChemomab Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChemomab Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Chemomab Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.88% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently increased by 4.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldChemomab Therapeutics does not currently pay a dividend.Dividend GrowthChemomab Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMMB. Previous Next 2.9 News and Social Media Coverage News SentimentChemomab Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Chemomab Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for CMMB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added Chemomab Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chemomab Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chemomab Therapeutics are expected to decrease in the coming year, from ($0.80) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemomab Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemomab Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemomab Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Chemomab Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Chemomab Therapeutics Stock (NASDAQ:CMMB)Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Read More CMMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMMB Stock News HeadlinesJuly 26 at 7:00 AM | globenewswire.comChemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price RequirementJuly 25 at 4:49 PM | finance.yahoo.comChemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital RaiseJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 25 at 4:49 PM | msn.comChemomab falls on private placement despite mid-stage win for lead assetJuly 25 at 11:48 AM | markets.businessinsider.comChemomab Reports Positive Results For Phase 2 Trial Of CM-101July 25 at 11:48 AM | msn.comChemomab Collapses on Private PlacementJuly 25 at 7:38 AM | globenewswire.comChemomab Therapeutics Announces $10 Million Private PlacementJuly 25 at 7:00 AM | globenewswire.comChemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing CholangitisJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 20, 2024 | americanbankingnews.comChemomab Therapeutics (NASDAQ:CMMB) Shares Down 0.9% June 6, 2024 | globenewswire.comChemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research ConferenceMay 17, 2024 | globenewswire.comChemomab Therapeutics to Participate in Upcoming Scientific ConferencesMay 14, 2024 | msn.comMaxim Group Initiates Coverage of Chemomab Therapeutics - Depositary Receipt () (CMMB) with Buy RecommendationMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)May 9, 2024 | investorplace.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024May 9, 2024 | globenewswire.comChemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comChemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleMay 2, 2024 | globenewswire.comChemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceSee More Headlines Receive CMMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMMB CUSIPN/A CIK1534248 Webwww.chemomab.com Phone972-77-331-0156FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+342.2%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-109.92% Return on Assets-83.68% Debt Debt-to-Equity RatioN/A Current Ratio3.83 Quick Ratio3.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book0.83Miscellaneous Outstanding Shares11,050,000Free Float9,734,000Market Cap$14.16 million OptionableNot Optionable Beta0.50 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Adi Mor George Ph.D. (Age 42)Co-Founder, Chief Scientific Officer, CEO & Executive Director Comp: $330kMs. Sigal Fattal CPA (Age 53)M.B.A., Chief Financial Officer Comp: $322kDr. Matthew B. Frankel M.B.A. (Age 55)M.D., Chief Medical Officer & VP of Drug Development Comp: $850kBarbara LindheimConsulting Vice President of Investor & Public Relations, Strategic CommunicationsKey CompetitorsOcuphire PharmaNASDAQ:OCUPFortress BiotechNASDAQ:FBIODURECTNASDAQ:DRRXAerovate TherapeuticsNASDAQ:AVTELantern PharmaNASDAQ:LTRNView All Competitors CMMB Stock Analysis - Frequently Asked Questions How have CMMB shares performed this year? Chemomab Therapeutics' stock was trading at $0.51 at the start of the year. Since then, CMMB stock has increased by 149.0% and is now trading at $1.27. View the best growth stocks for 2024 here. How were Chemomab Therapeutics' earnings last quarter? Chemomab Therapeutics Ltd. (NASDAQ:CMMB) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.08. How do I buy shares of Chemomab Therapeutics? Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMMB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
